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Ex vivo expanded hematopoietic progenitor cells improve
cardiac function after myocardial infarction: role of beta-catenin
transduction and cell dose
Abstract
Cell-based therapy after myocardial infarction (MI) is a promising therapeutic option but the relevant
cell subsets and dosage requirements are poorly defined. We hypothesized that cell therapy for
myocardial infarction is improved by ex vivo expansion and high-dose transplantation of defined
hematopoietic progenitor cells (HPCs). Since beta-catenin promotes self-renewal of stem cells we
evaluated the therapeutic efficacy of beta-catenin-mediated ex vivo expansion of mouse HPCs in a
mouse model of myocardial ischemia/reperfusion followed by intraarterial cell delivery. The impact of
cell dose was determined by comparing a low-dose (LD, 5 x 10(5) cells) vs. a high-dose (HD, 1 x 10(7)
cells) cell transplantation regimen of beta-catenin-HPCs. The impact of beta-catenin modification of
HPCs was determined by comparing control-transduced HPCs (GFP-HPCs) vs. transgenic
beta-catenin-HPCs. HD beta-catenin-HPCs significantly improved LV function and end-systolic and
end-diastolic dimensions as compared to saline and LD beta-catenin-HPCs. Furthermore, while
treatment with HD GFP-HPC resulted in a modest cardiac improvement the application of
beta-catenin-HPCs was superior, resulting in a significant improvement in EF, FS and LVESD over
saline and control GFP-HPC treatment. Although myocardial engraftment of HPCs was only transient,
as determined by cell quantification after dye labeling, beta-catenin-HPC treatment significantly
decreased infarct size, reduced cardiomyocyte apoptosis and increased capillary angiogenesis in vitro
and in vivo. Ex vivo expanded HPCs improve cardiac function and remodeling post MI in a cell
number- and beta-catenin-dependent manner.
Ex vivo expanded hematopoietic progenitor cells improve cardiac function 
after myocardial infarction: role of beta-catenin transduction and cell dose. 
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 Abstract 
 
Background: Although treatment with bone marrow stem cells is a promising therapy after 
myocardial infarction (MI) the cell subsets with therapeutic effects and dosage requirements 
are currently unknown. Since β-catenin promotes self-renewal of stem cells we hypothesized 
that defined mouse hematopoietic progenitor cells (HPCs), which we ex vivo expanded by β-
catenin gene transfer (β-catenin-HPCs) provide a promising tool for the treatment of MI.
Methods and results: The effects of ex vivo expanded HPCs were evaluated in a mouse 
model of myocardial ischemia/reperfusion followed by intraarterial cell delivery. The impact 
of cell dose was determined by comparing a low-dose (LD, 5 x 105 cells) vs. a high-dose 
(HD, 1 x 107 cells) cell transplantation regimen of β-catenin-HPCs. The impact of β-catenin 
modification of HPCs was determined by comparing control-transduced HPCs (GFP-HPCs) 
vs. transgenic β-catenin-HPCs. HD β-catenin-HPCs significantly improved LV function and 
end-systolic and end-diastolic dimensions as compared to saline and LD β-catenin-HPCs. 
Furthermore, while treatment with HD GFP-HPC resulted in a modest cardiac improvement 
the application of β-catenin-HPCs was superior, resulting in a significant improvement in EF, 
FS and LVESD over saline and control GFP-HPC treatment. Although myocardial 
engraftment of HPCs was only transient, as determined by cell quantification after dye 
labeling, β-catenin-HPC treatment significantly decreased infarct size, reduced 
cardiomyocyte apoptosis and increased capillary angiogenesis in vitro and in vivo, suggesting 
a paracrine mode of action. 
Conclusion: Ex vivo expanded mouse HPCs improve cardiac function and remodeling post 
MI in a threshold- and β-catenin-dependent manner. 
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 Introduction 
 
A leading cause of heart failure is myocardial ischemia, which precipitates dysfunction and 
death of cardiomyocytes [1]. The primary cardiac response to myocardial infarction (MI) is 
characterized by cardiomyocyte hypertrophy, apoptotic myocyte loss, progressive collagen 
replacement, and enlargement of the left ventricle [2, 3]. 
Cell transplantation is considered to represent a novel and promising therapeutic option to 
support endogenous regenerative mechanisms in ischemic heart disease and heart failure [5, 
6]. Recent studies suggest that bone marrow stem cells (BMCs) [7-10] and hematopoietic 
progenitor cells (HPCs) [11, 12] are useful in cell transplantation after MI. However, due to 
the heterogeneous nature of the used cell populations the most efficient cell type and required 
cell dose is currently unclear, and recent clinical trials have reported various outcomes [8, 9, 
13]. 
Furthermore, the relatively low number of progenitor cells and the difficulties of ex vivo 
expansion represent a major practical limitation. Therefore, genetic modification of stem cells 
might be an option to overcome these limitations in cell-based therapeutic applications. 
Recent studies indicate an important role of the canonical Wnt/β-catenin signaling pathway to 
enhance stem cell survival and expansion prior to cell therapy. For example, it has been 
shown that Wnt signaling promotes self-renewal of hematopoietic side populations, neuronal 
precursor cells, and embryonic stem cells [14-16]. Furthermore, gene transfer of 
constitutively active β-catenin prolonged the ex vivo expansion of HPCs up to two months 
[17]. 
Recently, we generated a multipotent mouse HPC line using β-catenin gene transfer with a 
lin-/Sca-1+/c-kit+ phenotype (β-catenin-HPCs) [18]. This cell line does not express pan 
surface markers of myeloid (CD11b, Gr-1, CD11c), erythroid (TER119), or lymphoid (B220, 
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 CD3e, NK1.1) lineages. Further, immunophenotypic characterization revealed a 
CD244+CD150-CD48- phenotype, which is consistent with the expression profile of 
multipotent hematopoietic progenitors. Continuous in vitro proliferation and expansion of β-
catenin-HPCs were associated with stabilized telomere length and consistent telomerase 
activity. As an immortalized mouse progenitor cell line, β-catenin-HPCs did not show 
evidence of leukemogenic potential [18]. 
We hypothesized that β-catenin-HPCs provide a promising tool for the treatment of MI. 
While recent studies combined models of permanent coronary occlusion with intramyocardial 
delivery of stem cells [5, 19, 20], established clinical practice mandates early coronary 
reperfusion post infarction followed by stem cell therapy. Accordingly, we established a 
mouse model of temporary coronary occlusion followed by reperfusion and intraarterial cell 
application into the ascending aorta. We show that administration of defined β-catenin-HPCs 
after MI reduces infarct size and improves left ventricle (LV) function and dimensions in a 
threshold-dependent manner. This effect is associated with improved angiogenesis and 
reduced apoptosis in the infarct border zone. Furthermore, β-catenin-HPCs have greater 
therapeutic efficacy than control-transduced HPCs, demonstrating a beneficial effect of β-
catenin transduction on myocardial repair. 
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 Methods 
 
Cell isolation and retroviral gene transfer 
Isolation of HPCs was performed as described previously [21]. In brief, lin- BM cells were 
isolated using a lineage depletion kit (Miltenyi Biotech, Bergisch Gladbach, Germany) and 
cell sorting via FACSAria (BD Biosciences, San Jose, CA, USA). GFP transduction of HPCs 
and generation of the β-catenin-HPC line was described previously [18]. Briefly, the human 
β-catenin cDNA was cloned into the retroviral vector SFβ-91-IRES-eGFP, and recombinant 
VSV-G pseudotyped retroviruses were generated in the packaging cell line Phoenix-gp. β-
catenin transduced cells stably expressed (> 99 %) hematopoietic stem cell markers Sca-1 
and c-kit. Cells were cultured in IMDM containing 10% FCS, 2 mM L-Glutamine, 1 % 
Penicillin-Streptomycin, 1 mM Non-essential amino acids, 5 x 10-5 M 2-mercaptoethanol, 10 
ng/ml rm-IL-3 and 50 ng/ml rm-SCF (all from Cell Systems, St. Katharinen, Germany). 
 
Experimental ischemia/reperfusion and cell injection 
All animal studies were in compliance with the Guide for the Care and Use of Laboratory 
Animals as published by the U.S. National Institutes of Health (NIH Publication No. 85-23, 
revised 1996) and were approved by the local animal care committees. Ischemia/reperfusion 
in mice and intraarterial injection of labeled cells were described previously [21]. Briefly, 
mice (age 10-12 weeks) were anesthetized and mechanically ventilated with isoflurane (1-
2%). A left thoracotomy was performed after which the left anterior descending artery (LAD) 
was ligated with 8-0 Prolone with a slipknot, which was removed 120 min later. Control mice 
underwent a thoracotomy and an incision of the pericard solely (sham). The thoracic wall was 
closed in layers. After extubation, all animals were allowed to recover from surgery in an 
incubator (37°C). 24 h after I/R washed cells were suspended in 200 µl PBS and injected into 
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 the aortic root via the left carotid artery of recipient mice. Five weeks after I/R and cell 
application cardiac function and diameter were quantified by echocardiography, magnetic 
resonance imaging (MRI) or left heart catheterization. 
For cell tracking cells were incubated in IMDM medium for 20 min at 37°C and finally 
labeled for 10 min at 37°C with 200 µM TAMRA [5-(and 6)-Carboxy-Tetramethylrhodamine 
Succinimidylester] (Molecular Probes) per 107 cells. Cell counts in the heart and in the spleen 
at 1 hour and 1 week after infusion of β-catenin-HPCs were made on 6 µm sections and 
surface area of the myocardium or spleen on the section was measured by planimetry. The 
cell number was referred to a certain tissue volume (mm3). Area at risk and early infarct size 
were assessed by Evan`s blue and 2,3,5-triphenyltetrazolium chloride staining 48 h after I/R 
as described [22]. MI size after 5 weeks was determined in haematoxylin- and eosin-stained 
sections using the Quantimet 500MC digital image analyzer as described previously [23]. 
 
Transthoracic echocardiography, hemodynamic measurement and Cine MRI 
Echocardiography was performed in sedated mice (ketamine, 100 mg/kg, and xylazine, 1.25 
mg/kg, i.p.) using a linear 15 MHz transducer (ATL HDI 5000 CV) as described [24]. In 
brief, short axis M-mode images were recorded at the papillary muscle level in sedated mice 
using a linear 15 MHz transducer (ATL HDI 5000 CV). Fractional shortening (FS) was 
calculated as follows: FS [%] = [(LVEDD-LVESD)/LVEDD] x 100 (LVEDD, left 
ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter). LV 
ejection fraction (EF) was calculated as [(LVEDA-LVESA)/LVEDA] x 100, where LVEDA 
and LVESA denote LV end-diastolic and end-systolic areas, respectively. Hemodynamic 
measurements were performed in mice under anesthesia using a 1.4 F micromanometer 
conductance catheter (SPR-719; Millar Instruments, Houston, TX) as described [25]. In brief, 
mice were anaesthetized and mechanically ventilated with enflurane (3%), a bilateral 
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 vagotomy was performed, and the catheter was inserted in the LV cavity via the right carotid 
artery. Cine MRI was performed on a 7.05 T-Biospec (Bruker, Ettlingen, Germany) using an 
ECG-triggered fast gradient echo FLASH sequence as described previously [26]. Briefly, ten 
to 12 contiguous ventricular short-axis slices of 1-mm thickness were acquired to cover the 
entire heart. Imaging parameters were as following: echo time TE = 1.6 ms; repetition time 
TR = 4.3 ms; field of view (30 mm2); acquisition matrix, 128 × 128. The resulting in plane 
resolution was 120 x 120 µm. Analysis of end-systolic and end-diastolic LV volumes and LV 
mass was done using an operator-interactive technique, and stroke volume and cardiac output 
were calculated, as previously described [27]. 
 
Analysis of capillary density and immunostaining 
Capillary density was determined 5 weeks after myocardial infarction in LV sections with 
transversely-sectioned cardiomyocytes immunostained against Isolectin B4 (Vector) and 
counterstained with WGA and Hoechst 33258 (Sigma) as described previously [23]. In brief, 
the ratio of Isolectin B4 positive cells to the total number of nuclei (Hoechst stain) per field 
was calculated. Capillaries per high power fields were determined in LV sections double 
stained for Isolectin B4 and WGA. For each mouse, high power fields (400 x; 200 µm x 200 
µm; 8 fields per section of LV basis, middle part and apex; n = 4) with transversely sectioned 
cardiomyocytes were digitally recorded to calculate the number of capillaries per high power 
field. 
 
TUNEL and Caspase-3 assay 
Apoptotic cardiomyocytes 48 h after MI were evaluated in serial paraffin sections by TUNEL 
assay with an ApopTag kit (Chemicon) in co-staining with an antibody against α-actinin 
(Sigma) as described previously [23]. Apoptotic morphology of nuclei was confirmed by 
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 counterstaining with DAPI. More than 20 tissue sections in each group were examined 
microscopically. Four fields each were selected in noninfarction and borderzone areas.
Caspase-3+ cardiomyocytes were evaluated 48 h after MI in serial paraffin sections. Staining 
was performed on 2µm sections. Slides were dewaxed by xylene, rehydrated by graded 
alcohol and epitope retrieval was carried out in a microwave oven as has been described 
previously. In brief, the slides were heated for 20 minutes (100°C) in 10mM sodium citrate 
(pH 6.0) and transferred to tris- buffered saline (TBS). Sections were stained using the 
Shandon coverplate system in a Tecan Genesis Autostainer (Shandon, Frankfurt a.M., 
Germany; Tecan, Deisenhofen, Germany). Tissue peroxidase activity was quenched by 
incubation with 3% hydrogen peroxide for 10 minutes, followed by rinse with TRIS buffer 
and a repeated protein blocking. The anti-Caspase 3 antibody (clone ASP 175; Cell Signaling 
Technology, Danvers, MA) was applied in a dilution of 1:80. For detection, a standard ABC-
method was used (ZytoChem Plus HRP, Zymed, San Francisco, CA). Counterstaining was 
done with Hemalaun, coverslips were mounted with Kaiser’s glycerine (Merck, Darmstadt, 
Germany). 
 
Cell migration and matrigel co-culture assays 
1 x 105 bone marrow derived HPCs or β-catenin-HPCs in 100 µl RPMI medium were placed 
in the upper chamber of transwell cell culture inserts (5-µm pore size; Costar, Cambridge, 
MA). The lower chamber contained 600 µl RPMI medium supplemented with stromal cell-
derived factor (SDF)-1 (100 ng/ml; Hölzel Diagnostika, Köln, Germany). Migration was 
carried out for 6 h at 37°C, 5% CO2 and the number of migrated cells was determined in a 
Neubauer counting chamber using an inverted cell culture microscope (magnification, 100 x; 
CKX31, Olympus, Hamburg, Germany). Network formation by human umbilical cord 
endothelial cells (HUVECs) after 24 hours was investigated in 48-well culture plates as 
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 recently reported. Wells were coated with 50 µL growth factor-reduced Matrigel (BD 
Biosciences, San Diego, CA) and seeded with 1.5 x 104 HUVECs and simultaneously with 
0.5 x 104 or 1.5 x 104 β-catenin HPCs using an inverted cell culture microscope 
(magnification, 40 x; CKX31, Olympus, Hamburg, Germany) and a digital camera (C-5060, 
Olympus, Hamburg, Germany). Vascular endothelial growth factor (VEGF) was used as 
positive control (50 ng/ml, PeproTech, Rocky Hill, NJ). Closed circular structures (tube-like 
structures) were quantified per well.
 
Statistical analysis 
Data are presented as mean ± SD. Differences between groups were analyzed by one-way 
ANOVA followed by Scheffe Post Hoc or Least Significant Difference (LSD) Post Hoc test, 
which was based on significant p-values in the ANOVA analysis. A P-value <0.05 was 
considered statistically significant. 
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 Results 
 
Transplantation of β-catenin-HPCs after I/R improves cardiac function in a threshold-
dependent manner 
Within the whole study period there was no difference in mortality between HPC treated 
animals and control treated animals: Sham (2/28), Saline (7/53), GFP-HPCs (1/11), β-
catenin-HPCs 5x105 (2/12), β-catenin-HPCs 1x107 (4/37). Of note, the intraoperative 
mortality due to the procedure of transcoronary cell delivery was 17 % (23/136). 
To evaluate the influence of cell dose of β-catenin-HPCs on myocardial function after MI we 
compared a low-dose cell transplantation regimen (LD, 5 x 105 cells) with a high-dose cell 
transplantation regimen (HD, 1 x 107 cells). Echocardiography 5 weeks after MI showed that 
LV systolic performance decreased and cardiac dimensions increased in saline-injected 
control hearts compared to sham-operated hearts (#P<0.01, Fig. 1, left panel, n = 10), 
demonstrating that our protocol of I/R induced severe myocardial dysfunction. The LD β-
catenin-HPC treatment strategy did not improve ejection fraction (EF) or fractional 
shortening (FS), but decreased left ventricle end-systolic dimension (LVESD) and left 
ventricle end-diastolic dimension (LVEDD) compared to saline treatment. In contrast, HD β-
catenin-HPC treatment showed significant improvement in EF and FS and decreased LVEDD 
and LVESD over saline and LD treated animals (*P<0.05, #P<0.01, Fig. 1, middle panel), 
indicating a threshold-dependent therapeutic effect of β-catenin-HPCs after MI. 
To determine the potential beneficial effect of transgenic β-catenin in HPCs we compared the 
effects of β-catenin-HPCs with control transduced HPCs (GFP-HPCs) at comparable cell 
numbers. Transplantation of β-catenin-HPCs resulted in a significant improvement in EF, FS 
and LVESD over saline and GFP-HPC treatment (*P<0.05, #P<0.01, Fig. 1, right panel), 
demonstrating that β-catenin expanded HPCs provide additional beneficial effect after MI. 
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 Cardiac magnetic resonance imaging 5 weeks after I/R and cell therapy confirmed the 
beneficial effects of β-catenin-HPCs observed by echocardiographic analysis. In fact, the 
detrimental effects of I/R on left ventricle end-systolic volume (LVESV), left ventricle end-
diastolic volume (LVEDV), LV mass and LV EF were completely prevented by β-catenin 
HPC treatment (#P<0.01, Fig. 2A, B, supplemental video 1-3, n = 4-6). 
Furthermore, invasive hemodynamic measurements demonstrated that cardiac output, 
+dp/dtmax (maximal rate of pressure rise), -dp/dtmax (maximal rate of pressure fall) and 
ejection fraction were significantly improved after HD β-catenin-HPC treatment (*P<0.05, 
#P<0.01, Fig. 3A, B, n = 8-12). 
 
HPCs show a transient myocardial engraftment after intraarterial delivery 
The migratory capacity of β-catenin HPC was not altered compared to freshly isolated HPC 
(Fig. 4A). To follow the fate of the transplanted cells, β-catenin-HPCs (1 x 107, n = 8 each) 
were labeled with TAMRA before intraarterial transcatheter injection and cell homing was 
analyzed by fluorescence microscopy. TAMRA+ cells were abundant in the myocardium at 1 
hour after delivery of 1 x 107 β-catenin-HPCs (n = 4, Fig. 4B), but were not detected after 1 
week (n = 4, Fig. 4B). In contrast, a substantial number of TAMRA+ cells were identified in 
the spleen after 1 hour and this number increased robustly 1 week after cell transplantation 
(Fig. 4B), suggesting redistribution of HPCs to the spleen as part of the hematopoietic 
compartment. The TAMRA+ cells detected in the myocardium were small, suggesting that 
the transplanted cells retained morphological characteristics of hematopoietic cells. 
 
Transplantation of β-catenin-HPCs reduces infarct size 
The effect of cell treatment on infarct size was determined 5 weeks after I/R. While LD 
treatment had no influence on infarct size, HD treatment with GFP-HPCs (1 x 107 cells, 
11 
 *P<0.05) or β-catenin-HPCs (1 x 107 cells, #P<0.01) reduced infarct size significantly 
compared to saline control. In addition, the effect of HD β-catenin-HPC treatment on infarct 
size was significantly better than GFP-HPC treatment (*P<0.05, Fig. 4C). 
To determine early protective effects of β-catenin-HPCs on infarct size hearts were analyzed 
48 hours after I/R. The size of the area at risk during left coronary occlusion was comparable 
in β-catenin-HPCs (n = 7) and saline injected (n = 6) hearts. However, infarct size was 
significantly smaller in β-catenin-HPC treated hearts (*P<0.05, Fig 4D), indicating that the 
protective effect of β-catenin-HPCs on infarct size is initiated early after MI. 
 
Transplantation of β-catenin-HPCs reduces myocardial apoptosis 
Smaller infarct size after I/R in animals treated with HD β-catenin-HPCs was associated with 
reduced apoptosis in cardiac cells in the borderzone reperfused area, yielding a 48 % 
reduction of TUNEL+ cells (*P<0.05, Fig. 5A) and a 70 % reduction of cleaved Caspase-3+ 
cells compared with saline injected hearts (#P<0.001, Fig. 5B). 
 
β-catenin-HPCs promote tube formation in vitro and capillary angiogenesis in vivo in a 
threshold-dependent manner 
To examine the effect of β-catenin-HPCs on the angiogenic potential of endothelial cells, a 
matrigel tube formation assay was employed. Co-culture of HUVECs with β-catenin-HPCs, 
in a threshold-dependent manner, significantly increased tube formation (Fig. 6A). 
Capillary density in the infarct border zone was significantly increased after HD β-catenin-
HPC treatment compared to control treatment (capillaries/cardiomyocytes: β-catenin-HPCs 
1.08 ± 0.11 vs. saline 0.91 ± 0.12, #P<0.01). In the remote myocardium, there was no 
difference between these groups (1.00 ± 0.13 vs. 0.94 ± 0.17; P=n.s., Fig. 6B). 
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 Discussion 
 
Although bone marrow cell therapy appears to provide beneficial effects post MI in 
experimental and clinical studies, major issues need to resolved, such as identification of cell 
subsets with therapeutic efficacy and characterization of dosage requirements of cell therapy. 
Furthermore, the use of bone marrow precursor cells is currently limited by the low 
frequency of cells obtained from bone marrow or other tissue. By employing  β-catenin gene 
transfer we recently generated a multipotent HPC line with a clearly defined lin-/Sca-1+/c-kit+ 
phenotype [18]. This cell line can be maintained in vitro for more than 36 months and 
displayed morphological and phenotypical characteristics of multipotent HPCs in vitro and in 
vivo [18]. Here, we demonstrate superior therapeutic efficacy of this defined subset of β-
catenin-expanded-HPCs (lin-/Sca-1+/c-kit+ HPCs) over control-transduced-HPCs. We further 
demonstrate that the therapeutic effect is threshold-dependent. 
To analyze the influence of cell dose on therapeutic efficacy we transplanted β-catenin-HPCs 
after I/R and compared the effects of a LD vs. a HD cell strategy 5 weeks after MI. LD cell 
therapy did not decrease infarct size and had only moderate effects on LV remodeling post 
MI, i.e. LVEDD and LVESD. In contrast, HD treatment decreased infarct size, improved LV 
function and improved LV remodeling compared to saline and LD treatment, indicating a 
threshold-dependent effect of HPC in myocardial cell therapy post MI. The protective effect 
of HD treatment on EF, LVESD and LVEDD was confirmed by MRT and further 
emphasized by invasive measurements, which showed increased cardiac output, cardiac 
contractility and relaxation after HD cell therapy compared to saline controls. 
Cell dosage requirements of HPCs might limit the efficacy of bone marrow cell therapy. For 
example, in the ASTAMI trial, the median number of mononuclear cells injected was 68 × 
106, and the median number of CD34+ cells was 0.7 × 106. There were no significant 
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 differences between the BMC and control group in changes in LVEF, end-diastolic volume, 
or infarct size [13]. In the BOOST trial, the average number of mononuclear BM cells was 
24.6 x 108, and the number of CD34+ cells was 9.5 x 106. Six months after randomisation, 
global LVEF increased from 50.0% to 56.7% (P=0.0026) [8]. In the TOPCARE-AMI trial, 
the average number of mononuclear BM cells was 24.5 x 107, and the number of CD34+ cells 
was 7 x 106. In patients receiving progenitor cells, global LVEF increased from 51.6% to 
60.1% (P=0.003) [9]. To treat a patient of 80 kg with a HD cell strategy as described here (1 
x 107 cells/25g) would require 32 x 109 CD34+ cells (adjusted to body weight), which 
exceeds the number of HPCs used in clinical trials by a factor of ~3000 [8, 28]. Our results 
suggest that techniques allowing rapid ex vivo HPC expansion may improve cell-based 
clinical treatment regimens. 
To address the therapeutic effects of HPC modification we treated mice with a HD treatment 
regimen and compared GFP-transduced-HPCs with β-catenin-transduced HPCs. Control-
HPCs had moderate, but significantly, improved LV remodeling and LV FS. However, β-
catenin-HPC treatment resulted in significant improvement of cardiac dimension and function 
over saline and control-HPCs. These observations suggest a therapeutic potential of β-catenin 
modification of HPC. However, uncontrolled nuclear accumulation of β-catenin can cause 
developmental defects and tumorigenesis in the adult organism. For example, mutations in β-
catenin and the GSK-3/APC/Axin complex, which regulates proteasome-mediated 
degradation of β-catenin, have also been found in sporadic colon cancers and a large variety 
of other tumor types (reviewed in Giles et al. 2003) [5]. 
As one alternative approach this carcinogenic risk could be reduced by employing inducible 
vector systems in future, facilitating a specific and tightly regulated controlled expression of 
β-catenin. Our previous study indicated that ectopic expression of β-catenin provides a 
reproducible tool for establishing HPC lines without evidence of malignant transformation 
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 and with responsiveness to external stimuli. 
To address the potential mechanisms by which HPCs improved cardiac function we evaluated 
long-term engraftment, myocardial apoptosis and angiogenesis. HPCs injected by a 
transcatheter, intraarterial approach did not show long-term myocardial engraftment (>24 
hours), but were readily detected in hematopoietic organs, such as the spleen, after longer 
time intervals. In addition, β-catenin-HPCs did not show migratory impairment in vitro 
compared to isolated HPCs. Although our results do not formally exclude transdifferentiation 
of HPCs into myocytes or endothelial cells, they support previous reports showing only 
transient myocardial homing of HPC after MI when cells were given by intraarterial route 
[21, 29]. In fact, the present observations are consistent with a paracrine mechanism of 
action. Paracrine factors released by stem and progenitor cells may stimulate cardiac 
angiogenesis and inhibit cardiac apoptosis. Previous studies reported that graft stem cells can 
secrete several important survival factors, such as vascular endothelial growth factor (VEGF), 
stromal cell-derived factor (SDF), basic fibroblast growth factor (bFGF), and insulin-like 
growth factor (IGF), which protect or salvage endangered ischemic myocardium [30]. 
Consistent with this hypothesis we observed increased capillary density and reduced 
myocardial apoptosis in the infarct border zone. Similarly, endothelial network expansion in 
vitro was enhanced by β-catenin-HPCs in a threshold-dependent manner. 
Our current study was not designed to investigate potential other indirect mechanisms that 
might improve cardiac function in the infarcted ischemic heart: Signaling molecules reported 
to be released by candidate cell types are known to mediate multiple potentially beneficial 
effects, including direct attenuation of increased efficiency of cardiomyocyte metabolism, 
e.g. as by IGF-1 [5] or interleukin-1 beta (IL-1β) [6], or modulation of inotropy [e.g., as by 
IFG-1 [7], bFGF [8, 9], or IL-1β [10, 11]. Benefits could also be produced by modulation of 
extracellular matrix (ECM) homeostasis by (a) reducing proteolysis of the heart’s existing 
15 
 ECM and preventing ventricular dilation; (b) hastening the formation of scar tissue, thereby 
halting ventricular dilation sooner; (c) reducing fibrosis in the noninfarcted region, thereby 
increasing compliance and diastolic function [12]. A final potential mechanism of action by 
which exogenous cell therapies may improve function in recently infarcted hearts is by 
promoting repair by endogenous progenitor cells, e.g. proliferation of resident stem cells and 
recruitment of non-resident cells. 
In summary, only high dose β-catenin-HPC transplantation caused a reduction in MI size, 
enhanced angiogenesis, and promoted anti-apoptotic effects, associated with improvement of 
cardiac function. Our data are consistent with the notion that the beneficial effects of β-
catenin-HPCs are, at least in part, attributable to protection of ischemic myocardium. Thus, 
our study suggests that ex vivo expansion of HPCs may be an attractive therapeutic option. 
Indeed, such an approach utilizing human HSCs or HPCs may yield unlimited cell quantities 
for clinical application. 
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 Figure Legends 
 
Figure 1: Echocardiographic parameters after transplantation of HPCs 
Echocardiographic parameters 5 weeks after MI and cell transplantation show higher ejection 
EF and FS and smaller LVESD and LVEDD in high dose (HD, 1 x 107 cells, n = 10) treated 
than in low dose (LD, 5 x 105 cells, n = 10) treated animals, indicating a threshold-dependent 
effect. Furthermore, a comparison of GFP-HPCs (n = 10) and β-catenin-HPCs (n = 10) 
revealed higher ejection EF and FS, smaller LVESD and increased SIST in β-catenin-HPC 
treated than in GFP-HPC treated animals, indicating a protective effect of transgenic β-
catenin in HPCs. 
EF: ejection fraction, FS: fractional shortening, LVESD: left ventricular end-systolic 
diameter, LVEDD: left ventricular end-diastolic diameter, SIST: systolic interventricular 
septum thickness. *<0.05 vs. saline, #P<0.01 vs. saline. Heart rates (bpm): sham (493 ± 22), 
saline (513 ± 16), GFP-HPC 1 x 107 (505 ± 27), β-catenin-HPC 5 x 105 (481 ± 25), β-catenin-
HPC 1 x 107 (518 ± 19). 
 
Figure 2: MRI analysis after transplantation of HPCs 
(A) Representative end-diastolic short axis images of sham-operated-, saline-treated- and β-
catenin-HPC treated (1 x 107 cells) hearts. * indicate papillary muscle.
(B) Functional assessment of myocardial function by magnetic resonance imaging. 
Measurements were obtained 5 weeks after MI in sham-operated- (n = 6), saline-treated (n = 
4), and β-catenin-HPC treated mice (1 x 107 cells, n = 5). 
EF: ejection fraction, LV mass: left ventricular mass, LVESV: left ventricular end-systolic 
volume, LVEDV: left ventricular end-diastolic volume. *P<0.05 vs. saline, #P<0.01 vs. 
saline. Heart rates (bpm): sham (377 ± 52), saline (400 ± 57), β-catenin-HPC 1 x 107 (360 ± 
69).
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Figure 3: Hemodynamic measurements after transplantation of HPCs 
(A) Representative pressure-volume loops in sham-operated-, saline-treated- and β-catenin-
HPC treated mice. 
(B) Functional assessment of myocardial function by hemodynamic parameters. 
Measurements were obtained 5 weeks after I/R. Cardiac output, +dP/dt max (maximal rate of 
pressure rise) and -dP/dt max (maximal rate of pressure fall) in sham-operated- (n = 10), 
saline-treated- (n = 12) and β-catenin-HPC treated mice (1 x 107 cells, n = 8). *P<0.05 vs. 
saline, #P<0.01 vs. saline. Heart rates (bpm): sham (476 ± 52), saline (462 ± 56), β-catenin-
HPC 1 x 107 (443 ± 54).
 
Figure 4: Engraftment of HPCs and histomorphometric analysis 
(A) Migration of bone marrow derived HPCs and β-catenin-HPCs was carried out in the 
presence of 100 ng/ml SDF-1 for 6 hours (n = 3). 
(B) Upper panel: Quantification of engrafted β-catenin-HPCs (1 x 107) in myocardium and 
spleen 1 hour and 1 week after cell transfer (n = 4 each group). #P<0.01 vs. 1 hour. 
Lower panel: Direct fluorescence microscopy of heart and spleen sections after intraarterial 
delivery of TAMRA-labeled β-catenin-HPCs 1 hour and 7 days after cell transfer. Blue: 
nuclei (DAPI), red: TAMRA+ β-catenin HPCs. Scale bar = 50 µm.
(C) Administration of β-catenin-HPCs into ischemic mouse hearts reduced infarct size. 
Quantification of infarct size by morphometric analysis in saline-, GFP- (1 x 107), and β-
catenin-HPC (5 x 105, 1 x 107) treated mice. *P<0.05 vs. saline, #P<0.01 vs. saline. 
(D) Area at risk (AAR) and infarct sizes were determined by Evans Blue and TTC staining. 
Left panel: Representative cross-sections are shown. The area of the myocardium not stained 
with Evans blue represents the AAR, infarcted areas appear pallid (highlighted with beige), 
and viable myocardium appears pink (highlighted with pink). 
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 Right panel: AAR and infarcted area (MI) were expressed as percentage of LV cross-sectional 
area (LV); MI was also calculated as percentage of AAR. *P<0.05 vs. saline. 
 
Figure 5: Transplantation of β-catenin-HPCs reduces myocardial apoptosis 
(A) Left panel: Apoptotic cells in the infarct border zone were detected by TUNEL/DAPI 
staining and α-actinin immunostaining. Representative sections are shown: TUNEL (left), 
DAPI (middle), TUNEL/DAPI/α-actinin overlay (right). Scale bar = 50 µm.
Right panel: TUNEL+ cells in the infarct border zone. Data from saline injected mice (n = 6) 
and β-catenin HPC treated mice (n = 7) are shown. *P<0.05 vs. saline. 
(B) Left panel: Apoptotic cells in the infarct border zone were detected by anti-cleaved 
Caspase-3 staining. Representative myocardial sections are shown: overview (left), higher 
magnification (right). Scale bar = 60 µm.
Right panel: Cleaved Caspase-3+ cells in the infarct border zone. Data from saline injected 
mice (n = 6) and β-catenin-HPC treated mice (n = 7) are shown. #P<0.001 vs. saline. 
 
Figure 6: β-catenin HPCs promote angiogenesis in vitro and in vivo 
(A) Left panel: 1.5 x 104 HUVECs were cultured in matrigel for 24 hours in the absence 
(control) or in the presence of 50 ng/ml VEGF or co-cultured with 0.5x104 and 1.5x104 β-
catenin-HPCs (original magnification: 40 x). Scale bar = 500 µm.
Right panel: β-catenin-HPCs promote tube formation of endothelial cells in vitro in a cell 
concentration-dependent manner. Tube-like structures from 3 independent experiments were 
quantified. Increase in tube-like structures was significant different from control levels 
(*P<0.05, #P<0.01). 
(B) 
(C) 
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 (D) Left panel: Transplantation of β-catenin-HPCs increased capillary density in the 
borderzone after I/R. Representative cross-sections of the myocardium stained with Isolectin 
B4, WGA and Hoechst 33258 are shown. Scale bar = 50 µm.
Right panel: Myocardial capillary density in infarct borderzone and remote myocardium 5 
weeks after I/R in saline- and β-catenin-HPC treated hearts (n = 8 each group). #P<0.01 vs. 
saline. 
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